JP5543956B2 - 癌の処置のための方法および組成物 - Google Patents

癌の処置のための方法および組成物 Download PDF

Info

Publication number
JP5543956B2
JP5543956B2 JP2011501983A JP2011501983A JP5543956B2 JP 5543956 B2 JP5543956 B2 JP 5543956B2 JP 2011501983 A JP2011501983 A JP 2011501983A JP 2011501983 A JP2011501983 A JP 2011501983A JP 5543956 B2 JP5543956 B2 JP 5543956B2
Authority
JP
Japan
Prior art keywords
cisplatin
treatment
cancer
arsenic
sodium meta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011501983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515481A (ja
JP2011515481A5 (https=
Inventor
アンジェリカ バーガー，
ハンス ヘンドリクス，
ベルナルダス ラデマーカー，
Original Assignee
コミノックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コミノックス・インコーポレイテッド filed Critical コミノックス・インコーポレイテッド
Publication of JP2011515481A publication Critical patent/JP2011515481A/ja
Publication of JP2011515481A5 publication Critical patent/JP2011515481A5/ja
Application granted granted Critical
Publication of JP5543956B2 publication Critical patent/JP5543956B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011501983A 2008-03-27 2009-03-24 癌の処置のための方法および組成物 Expired - Fee Related JP5543956B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3998708P 2008-03-27 2008-03-27
US61/039,987 2008-03-27
US12/408,864 US20090246291A1 (en) 2008-03-27 2009-03-23 Method and compositions for treatment of cancer
US12/408,864 2009-03-23
PCT/US2009/038104 WO2009120697A2 (en) 2008-03-27 2009-03-24 Method and compositions for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014046212A Division JP2014101387A (ja) 2008-03-27 2014-03-10 癌の処置のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2011515481A JP2011515481A (ja) 2011-05-19
JP2011515481A5 JP2011515481A5 (https=) 2012-04-05
JP5543956B2 true JP5543956B2 (ja) 2014-07-09

Family

ID=41114644

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011501983A Expired - Fee Related JP5543956B2 (ja) 2008-03-27 2009-03-24 癌の処置のための方法および組成物
JP2014046212A Withdrawn JP2014101387A (ja) 2008-03-27 2014-03-10 癌の処置のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014046212A Withdrawn JP2014101387A (ja) 2008-03-27 2014-03-10 癌の処置のための方法および組成物

Country Status (20)

Country Link
US (2) US20090246291A1 (https=)
EP (1) EP2268292B1 (https=)
JP (2) JP5543956B2 (https=)
KR (1) KR101634138B1 (https=)
CN (2) CN102046187A (https=)
AU (1) AU2009228378B2 (https=)
BR (1) BRPI0909164A2 (https=)
CA (1) CA2719766C (https=)
CY (1) CY1120536T1 (https=)
DK (1) DK2268292T3 (https=)
ES (1) ES2656762T3 (https=)
HU (1) HUE036609T2 (https=)
LT (1) LT2268292T (https=)
MX (1) MX2010010621A (https=)
PL (1) PL2268292T3 (https=)
PT (1) PT2268292T (https=)
RU (1) RU2508116C2 (https=)
SI (1) SI2268292T1 (https=)
WO (1) WO2009120697A2 (https=)
ZA (1) ZA201006988B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504587A (ja) * 2009-09-10 2013-02-07 コミノックス・インコーポレイテッド 癌幹細胞を標的とした薬剤耐性癌治療法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8795738B2 (en) * 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
WO2012012305A2 (en) * 2010-07-18 2012-01-26 Niiki Pharma Inc. Combination therapy using a ruthenium complex
JP5997156B2 (ja) * 2010-08-24 2016-09-28 ジーティーエックス・インコーポレイテッド 癌の治療のための化合物
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
CA2835631A1 (en) * 2011-05-12 2012-11-15 Board Of Regents, The University Of Texas System Use of arsenic for cancer therapy protection
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US20160184356A1 (en) * 2013-03-15 2016-06-30 Ke Jian Jim Liu Arsenic-based treatment of cancers and inflammatory disorders
KR101309844B1 (ko) 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
MX372671B (es) * 2013-07-19 2020-04-23 Onyx Therapeutics Inc Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
CA3041357A1 (en) * 2016-12-01 2018-06-07 Eupharma Pty Ltd Diarsenic tetraoxide compositions and their use in the treatment of cancers
KR102868121B1 (ko) * 2018-03-22 2025-10-14 코미팜 인터내셔널 오스트레일리아 피티와이 엘티디 메타 아비산염을 포함하는 약학 조성물 및 제조 방법
CN116236505A (zh) * 2023-03-15 2023-06-09 上海市第四人民医院 三氧化二砷在制备肺神经内分泌癌治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
TR200002243T2 (tr) * 1997-11-10 2000-12-21 Memorial Sloan-Kettering Cancer Center Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
WO2003086424A1 (en) * 2002-04-10 2003-10-23 Korea Microbiological Laboratories, Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8097237B2 (en) * 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
US7867492B2 (en) * 2007-10-12 2011-01-11 The John Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504587A (ja) * 2009-09-10 2013-02-07 コミノックス・インコーポレイテッド 癌幹細胞を標的とした薬剤耐性癌治療法

Also Published As

Publication number Publication date
SI2268292T1 (en) 2018-03-30
PT2268292T (pt) 2018-02-19
EP2268292B1 (en) 2017-12-27
AU2009228378A1 (en) 2009-10-01
CA2719766C (en) 2017-10-31
BRPI0909164A2 (pt) 2016-06-21
CN102046187A (zh) 2011-05-04
PL2268292T3 (pl) 2018-06-29
CA2719766A1 (en) 2009-10-01
WO2009120697A3 (en) 2010-02-18
ES2656762T3 (es) 2018-02-28
EP2268292A2 (en) 2011-01-05
WO2009120697A2 (en) 2009-10-01
ZA201006988B (en) 2012-05-30
EP2268292A4 (en) 2011-05-11
US20090246291A1 (en) 2009-10-01
WO2009120697A4 (en) 2010-04-15
CY1120536T1 (el) 2019-07-10
LT2268292T (lt) 2018-03-26
CN104997808A (zh) 2015-10-28
MX2010010621A (es) 2011-04-05
JP2014101387A (ja) 2014-06-05
JP2011515481A (ja) 2011-05-19
KR101634138B1 (ko) 2016-06-28
DK2268292T3 (en) 2018-03-12
HUE036609T2 (hu) 2018-07-30
KR20110009664A (ko) 2011-01-28
AU2009228378B2 (en) 2014-07-17
US20180055812A1 (en) 2018-03-01
RU2508116C2 (ru) 2014-02-27
RU2010143893A (ru) 2012-05-10

Similar Documents

Publication Publication Date Title
JP5543956B2 (ja) 癌の処置のための方法および組成物
CN102105152B (zh) 包含cdks抑制剂和抗肿瘤剂的治疗组合
EP2435041B1 (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
JP2019508433A (ja) Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法
EP2049121B1 (en) Compositions for promoting activity of anti-cancer therapies
JP2009536956A (ja) 抗癌治療法
TW201509413A (zh) 含有亞鐵胺基酸螯合物之組合物用於製造抗癌症之醫藥品的用途
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
US9937261B2 (en) Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy
JP2014144979A (ja) 治療におけるアポトーシスを増加させるための有糸分裂の阻害剤
Jing et al. Trifluoperazine synergistically potentiates bortezomib-induced anti-cancer effect in multiple myeloma via inhibiting P38 MAPK/NUPR1
JP2021063014A (ja) 白血病治療薬
CN101167741B (zh) 莱菔硫烷和铂类药的抗癌联合制剂
EP3565547B1 (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
WO2020254299A1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
US6593303B1 (en) Anti-tumor synergetic composition
HK1152250B (en) Method and compositions for treatment of cancer
HK1152250A (en) Method and compositions for treatment of cancer
KR20060036058A (ko) 결장직장암의 치료를 위한 혈관 손상 활성을 갖는 5ｆｕ,ｃｐｔ-11 또는 5-ｆｕ 및 ｃｐｔ-11과 함께 ｚｄ6126을포함하는 조성물
EP3854411A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
HK40092504A (zh) 治疗癌症的bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物
HK40060452A (en) COMBINED USE OF A-NOR-5α ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140310

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140509

R150 Certificate of patent or registration of utility model

Ref document number: 5543956

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees